» Articles » PMID: 31190965

Tapentadol for Neuropathic Pain: a Review of Clinical Studies

Overview
Journal J Pain Res
Publisher Dove Medical Press
Date 2019 Jun 14
PMID 31190965
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

Neuropathic pain (NP) is an enormous burden for patients, caregivers and society. NP is a pain state that may develop after injury of the peripheral or central nervous system because of a wide range of diseases and traumas. A NP symptom component can be found also in several types of chronic pain. Many NP patients are substantially disabled for years. Due to its chronicity, severity and unpredictability, NP is difficult to treat. Tapentadol is a central-acting oral analgesic with combined opioid and noradrenergic properties, which make it potentially suitable for a wide range of pain conditions, particularly whenever a NP component is present or cannot be excluded. In randomized controlled trials, tapentadol has proved to be effective in relieving NP in diabetic peripheral neuropathy and in chronic low back pain. In observational studies, tapentadol reduced NP in chemotherapy-induced peripheral neuropathies, blood and solid cancers, and the NP component in neck pain and Parkinson's disease. This narrative review aims to provide clinicians with a broad overview of tapentadol effects on NP.

Citing Articles

Metabotropic Glutamate Receptor 5: A Potential Target for Neuropathic Pain Treatment.

Manengu C, Zhu C, Zhang G, Tian M, Lan X, Tao L Curr Neuropharmacol. 2024; 23(3):276-294.

PMID: 39411936 PMC: 11808587. DOI: 10.2174/1570159X23666241011163035.


Opioid system and related ligands: from the past to future perspectives.

Rullo L, Morosini C, Lacorte A, Cristani M, Coluzzi F, Candeletti S J Anesth Analg Crit Care. 2024; 4(1):70.

PMID: 39390585 PMC: 11468104. DOI: 10.1186/s44158-024-00201-2.


Sex-Gender Differences Are Completely Neglected in Treatments for Neuropathic Pain.

Salis F, Sardo S, Finco G, Gessa G, Franconi F, Agabio R Pharmaceuticals (Basel). 2024; 17(7).

PMID: 39065689 PMC: 11280170. DOI: 10.3390/ph17070838.


Assessment for Diabetic Neuropathy: Treatment and Neurobiological Perspective.

Bhrigu B, Sharma S, Kumar N, Banik B Curr Diabetes Rev. 2024; 21(6):12-31.

PMID: 38798207 DOI: 10.2174/0115733998290606240521113832.


Pharmacological Treatments and Therapeutic Drug Monitoring in Patients with Chronic Pain.

De Rosa F, Giannatiempo B, Charlier B, Coglianese A, Mensitieri F, Gaudino G Pharmaceutics. 2023; 15(8).

PMID: 37631302 PMC: 10457775. DOI: 10.3390/pharmaceutics15082088.


References
1.
Fishbain D, Cole B, Lewis J, Gao J . What is the evidence that neuropathic pain is present in chronic low back pain and soft tissue syndromes? An evidence-based structured review. Pain Med. 2013; 15(1):4-15. DOI: 10.1111/pme.12229. View

2.
Schwartz S, Etropolski M, Shapiro D, Okamoto A, Lange R, Haeussler J . Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebo-controlled trial. Curr Med Res Opin. 2010; 27(1):151-62. DOI: 10.1185/03007995.2010.537589. View

3.
Pergolizzi J, Alon E, Baron R, Bonezzi C, Dobrogowski J, Galvez R . Tapentadol in the management of chronic low back pain: a novel approach to a complex condition?. J Pain Res. 2011; 4:203-10. PMC: 3160833. DOI: 10.2147/JPR.S19625. View

4.
Coluzzi F, Raffa R, Pergolizzi J, Rocco A, Locarini P, Cenfra N . Tapentadol prolonged release for patients with multiple myeloma suffering from moderate-to-severe cancer pain due to bone disease. J Pain Res. 2015; 8:229-38. PMC: 4431495. DOI: 10.2147/JPR.S83490. View

5.
Baron R, Kennes L, Elling C . Retrospective analyses versus RCTs: comparing like with like?. J Pain Res. 2017; 10:783-786. PMC: 5386600. DOI: 10.2147/JPR.S133369. View